Therefore, our results call for cautious use of anti-IL-6-STAT3 signalling blockers in the treatment of PCa as this may turn low-grade tumours into highly malignant cancers by loss of senescence controlled by the STAT3–ARF axis. This evidence concerns the gene CDKN2A and cancer.